The total sales of NEVs in China surpassed 40 million units, according to CCTV. The production and sales consecutively ranked first globally for 10 years, contributing to global carbon reduction goals.
~

AASTOCKS Financial News
Website: www.aastocks.com

As the golden September and silver October consumption peak season begins, large autumn car shows are being launched successively, while dealers are promoting sales at the end of the quarter with stronger marketing efforts, the China Automobile Dealers Association (CADA) released a passenger car market report saying.

Coupled with the dual festival effect of 'Mid-Autumn Festival + National Day' holidays, consumer demand for car purchases will be rapidly released, supporting a continuous rise in terminal sales in September.

Based on the sales in August and the growth rate of dealer data in the first half of September, it is expected that the total passenger car terminal sales in September will reach 2.2 million units.
~

AASTOCKS Financial News
Website: www.aastocks.com

SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported a clinical update on IBI324 (Ollin R&D code: OLN324). IBI324 (OLN324) is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody in Phase 1b clinical development for patients with either wet (neovascular) age-related macular degeneration (wAMD) or diabetic macular edema (DME), the leading causes of vision loss in older and working-aged people, respectively. Ollin has completed enrollment of over 150 patients with wAMD or DME in the JADE study, a randomized, U.S.-based, Phase 1b proof-of-concept clinical trial designed to evaluate OLN324 versus faricimab for potential areas of anatomic and durability differentiation. Topline results from the study are expected in the first quarter of 2026.

Building on the proven backbone efficacy of anti-VEGF, OLN324's substantially higher anti-Ang2 potency over the current market leader faricimab, coupled with a smaller protein format, gives OLN324 the potential for best-in-class disease control. OLN324 is being tested at higher molar doses than faricimab for greater target coverage and the potential for extended treatment durability. These features give OLN324 the potential for a differentiated, first-line standard of care profile.

"Both VEGF and Ang2 play important roles in the vascular pathologies that drive wAMD and DME. Dual targeting has the potential to improve anatomic outcomes and achieve more durable disease control compared to VEGF inhibition alone. Uptake of the first U.S. FDA-approved VEGF/Ang2 inhibitor, faricimab, underscores the interest from retinal specialists and patients for new medicines offering improved outcomes by targeting more than one driver of disease," said Charles C. Wykoff, MD, PhD, Chairman of Research, Retina Consultants of America, and member of Ollin's Scientific Advisory Board. "There remains meaningful room for further clinical improvement for patients. Ollin's Phase 1b study explores the potential for differentiation of OLN324 versus faricimab from the outset."

Dr. Lei Qian, Chief R&D Officer of General Biomedicine from Innovent Biologics, stated: "We are excited about by the progress of OLN324 (IBI324), driven forward by our partner Ollin—especially the successful enrollment completion of the JADE Phase 1b trial, which represents a key milestone that validates both parties' strong collaboration. As a next-generation VEGF/Ang-2 bispecific antibody, OLN324 (IBI324) holds promise for better anatomic outcomes and longer durability than current standards like faricimab. We remain aligned with Ollin to speed OLN324's development and bring this much needed therapy to market globally."

In a completed Phase 1 single and multiple dose escalation study, IBI324 (OLN324) demonstrated promising vision and anatomic improvements in DME patients along with a favorable safety profile. IBI324 (OLN324) was discovered by Innovent and is being developed in collaboration with Ollin.

About Ollin

Established in 2023, Ollin Biosciences^TM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. For more information, please visit www.ollin.bio.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s).

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

As expected, the Fed has announced its first rate cut since December 2024, lowering the benchmark overnight rate by a quarter percentage point to 4-4.25%.

Fed Chairman Jerome Powell, after the meeting, described this rate cut as a risk management cut instead of the beginning of a long-term rate cut cycle.

The US stock market went through turbulence on Wednesday. The DJIA hit a new high after the announced rate cut, closing up 260 points or 0.6% at 46,018. The S&P 500 fell 6 points or 0.1% throughout the day, barely holding onto 6,600. The Nasdaq ended down 72 points or 0.3% at 22,261.

Tech stocks retreated across the board. Nvidia (NVDA.US) slipped 2.6% at close amid reports that it has been banned by China from selling its chips to tech companies in the country.

In contrast, Walmart (WMT.US), JPMorgan (JPM.US), and American Express (AXP.US) rallied on the back of lower interest rates, driving the DJIA and the overall market upward.
~



AAStocks Financial News
Web Site: www.aastocks.com

Weeks before the launch of Apple (AAPL.US)'s iPhone 17 series, sales of Apple's phones dropped by 6% YoY in China, a decline steeper than that seen before previous new releases, according to foreign media reports that cited data from Counterpoint Research.

Likewise, phone makers, including XIAOMI-W (01810.HK), vivo, and HONOR, also recorded sales falls in the first eight weeks of 3Q25. From July to August, the overall Chinese mobile phone market shrank by 2%, despite China's launch of large-scale consumption subsidies.
~



AAStocks Financial News
Web Site: www.aastocks.com

WUXI, China, Sept. 17, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – MFG1, MFG2, and DP5 – have received GMP certification from Türkiye İlaç ve Tıbbi Cihaz Kurumu (TITCK). This marks the first GMP inspection conducted by Turkey's TITCK at WuXi Biologics. Achieving the certification underscores the company's commitment to upholding stringent international quality standards across its global network.

During the five-day onsite inspection of two monoclonal antibody biologics produced by WuXi Biologics for its clients, the three manufacturing facilities successfully passed TITCK's comprehensive assessment, validating the company's capabilities in providing high-quality services for global clients. All of these facilities have previously received approval from other major regulatory authorities for the development of multiple biologic therapeutics.

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry's most rigorous quality standards. As of the end of June 2025, it has successfully passed 44 regulatory inspections, including 22 conducted by the FDA and the EMA. The company also holds an industry-leading achievement with a 100% pass rate for Pre-License Inspection (PLI) by the FDA. Additionally, WuXi Biologics has passed more than 1,700 GMP quality audits by global clients, including more than 200 audits by EU Qualified Persons. Currently, the company operates 16 GMP-certified drug substance and drug product facilities within its global network. Its world-class quality and compliance capabilities remain the cornerstone of clients' trust.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are delighted to receive GMP certification from Turkey's TITCK—our first recognition in the Turkish market, and a clear sign of WuXi Biologics' capability to tap into emerging markets. With a deep understanding that quality is crucial to ensuring safety and efficacy in the global pharmaceutical industry, we are steadfast in upholding the highest standards across our entire network. Looking forward, WuXi Biologics will continue building on our first-class quality system and exceptional service capabilities, remaining dedicated to enabling our clients in bringing high-quality biologics to patients worldwide."

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain. 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts

Business
[email protected]

Media
[email protected]

Investors took profits ahead of the Fed's monetary policy meeting, with the market focusing on the Fed's 2-day monetary policy meeting. US stocks weakened on Tuesday.

The S&P 500 hit another new all-time high shortly after the market opened, and reached 6,626 before falling. The index closed 8 points lower at 6,606. The Nasdaq fluctuated after setting a new high, and slid 14 points to 22,333. The DJIA ebbed 125 points or 0.3% to close at 45,757.

Techs were generally under pressure, with Nvidia (NVDA.US) and Microsoft (MSFT.US) slipping 1.6% and 1.2% respectively. Palantir (PLTR.US) and Alphabet (GOOG.US) also declined. Tesla (TSLA.US) continued to jump up by over 2.8%.

US and Chinese officials completed talks in Madrid this week, and reached a framework agreement regarding TikTok, allowing the app to continue operating in the US.

Oracle (ORCL.US) will assist TikTok in continuing its operations in the US, which boosted Oracle's share price by 1.5%, according to foreign media.
~

AASTOCKS Financial News
Website: www.aastocks.com

Launch of AI Agent Development Platform 3.0, available internationally via Tencent Cloud, at the 2025 Global Digital Ecosystem Summit

Tencent Cloud's overseas client base doubled since last year; achieved high double-digit year-over-year growth over the past three years

SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- Tencent today announced the global roll-out of new scenario-based AI capabilities, empowering enterprises across diverse industries to accelerate industry efficiency and advance international growth. Announced at the 2025 Tencent Global Digital Ecosystem Summit, held at the Shenzhen World Exhibition & Convention Center from 16 to 17 September, it comprises a suite of intelligent agent applications, "SaaS + AI" solutions and large model technological upgrades.

"Truly usable and practical AI applications drive industrial efficiency, while internationalization charts new growth possibilities," said  Dowson Tong, Senior Executive Vice President of Tencent and CEO of the Cloud and Smart Industries Group. "Our newly launched and upgraded solutions will support enterprises in their intelligence and internationalization journey as they build scalable and sustainable growth."

Accelerating Implementation of Intelligent Solutions

The Tencent Cloud Intelligent Agent Strategy Panorama highlighted the global launch of Agent Development Platform 3.0 (ADP), which enables enterprises to generate and integrate intelligent, autonomous AI agents into their workflows, for scenarios such as customer service, marketing, inventory management, research, and more. Tencent is continuously iterating on various intelligent agent development frameworks like LLM+RAG, Workflow, and Multi-Agent, to help enterprises efficiently build stable, secure, and business-aligned agents using proprietary data. In addition, AI Infra's "Agent Runtime" was also launched to provide a robust infrastructure foundation for building, deploying, and operating AI agents.

The upgraded SaaS+AI toolkit enhances office collaboration, including AI Minutes in Tencent Meetings, which has seen a year-on-year growth rate of 150% over the past year. It also supports knowledge management, such as Tencent LearnShare, currently used by over 300,000 enterprises enjoying 92% response accuracy. CodeBuddy, an AI-powered AI coding tool for developers, reduces coding time by 40% and increases R&D efficiency by 16%.

New models powered by Hunyuan, Tencent's proprietary large language model, were announced, including Hunyuan 3D 3.0, Hunyuan 3D AI and Hunyuan 3D Studio, imbued with cutting-edge 3D generation capabilities for creators and developers in media and gaming industries, and more. Hunyuan 3D series models have been downloaded over 2.6 million times on Hugging Face, making them the most popular open-source 3D models globally.

Over the past year, Tencent's Hunyuan large model has released more than 30 new models and fully embraced open-source development. It has gradually open-sourced models such as the hybrid inference model Hunyuan-A13B and a translation model supporting over 30 languages, along with comprehensive multimodal generation capabilities and tools for image, video and 3D content.

Fully Embrace Internationalization

At the summit, Tencent Cloud highlighted its milestones in global expansion, noting that its overseas client base has doubled since last year. Over the last three years, Tencent Cloud International has achieved high double-digit year-over-year growth globally, across Asia markets, namely Hong Kong, Southeast Asia, Japan, and more.

Today, more than 90% of leading Chinese internet companies, and 95% of leading Chinese gaming companies are also using Tencent Cloud to support their global expansion initiatives.

During the Tencent Cloud International Summit held in the afternoon, Tencent's global partners including Converge Information and Communications Technology Solutions, DANA, e& UAE, Hong Kong Jockey Club, Fusion Bank, GoTo Group, Indosat Ooredoo Hutchison (IOH), Miniclip, MUFG Bank (China), Prosus, True IDC, and more, discussed the need for enterprises to adopt advanced cloud and AI solutions to power their next stage of growth and internationalization ambitions.

Poshu Yeung, Senior Vice President, Tencent Cloud International said, "Tencent Cloud brings to overseas enterprises our deep expertise and experience in integrating AI across our ecosystem. With the launch of new solutions such as Tencent Cloud Agent Development Platform, we hope to expand our reach globally, and serve wider industries and enterprise use-cases."

The summit also saw Tencent Cloud International signing partnership agreements with global enterprises, from Asia Pacific companies including Datacom, IOH, Gardi Management, GoTo Group, MahakaX, MUFG Bank (China), RYDE Technologies, StoneLink, True IDC, 99 Group; to Middle Eastern companies including Coop Bank Oromia and Nativex; European companies including eMAG; and North American company InCloud.

Tencent will upgrade its Tencent Cloud internationalization strategy across three areas — infrastructure, technology products, and service capabilities — to help more enterprises across different industries to transform digitally. Today Tencent Cloud products like the Superapp-as-a-Service solution and PalmAI have been widely embraced by overseas enterprises from Asia Pacific, the Middle East and The Americas.

Tencent Cloud has introduced international versions of products such as Tencent Cloud Agent Development Platform (TCADP), CodeBuddy and Cloud Mall. These globalized solutions are designed to better accommodate local requirements and provide reliable support for high-concurrency enterprises worldwide. For instance, its EdgeOne security and acceleration platform recently integrated large language models with the Model Context Protocol (MCP) Server, resulting in the launch of EdgeOne Pages. This development significantly enhanced developer efficiency by reducing website development and deployment time from one day to merely one minute. Within three months, the platform garnered over 100,000 global users.

Tencent Cloud operates 55 data centres across 21 markets and regions, and plans to invest USD150 million in the future to build its first Middle East data center in Saudi Arabia. Simultaneously, it will build a third data center in Osaka, Japan, and establish a new Osaka office. Today, Tencent Cloud has deployed 9 global technical support centers in Jakarta, Manila, Kuala Lumpur, Singapore, Bangkok, Tokyo, Seoul, Palo Alto, and Frankfurt.

SHENZHEN, China, Sept. 16, 2025 /PRNewswire/ -- The 2025 IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS 2025), a premier global event in the robotics field, will be held from October 19 to 25, 2025 at the Hangzhou International Expo Center. This will be the first time in nearly two decades that the conference returns to mainland China since 2006.

During the conference, RoboSense will participate as an official sponsor and unveil its latest innovation in its Active Camera Series – the AC2. The introduction of AC2 aims to provide robotics researchers and developers worldwide with a more powerful perception development tool. It accelerates cutting-edge research and streamlines the commercialization of AI-driven robotics applications.

The AC2 is designed to meet diverse application scenarios in the embodied intelligent robotics industry, delivering high-precision and highly robust RGBD information. Integrated with AI algorithms, it enables robots to perceive 3D environments and semantic information with stability and accuracy, effectively utilizing this information to achieve task-oriented goals. This empowers developers to significantly simplify the perception development process and improve efficiency.

At the upcoming IROS conference, RoboSense will showcase a comprehensive portfolio of its technological achievements in robotics, including the multi-sensor integrated product AC1, the AI-Ready developer ecosystem, and next-generation digital LiDAR solutions specifically designed for robots, such as the E1R and Airy. Additionally, live demonstrations of dexterous hand technology will also be conducted.

Widely regarded as the Olympics of robotics research, the IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS) has maintained exceptional academic influence and extensive industry engagement since its establishment in 1988, consistently driving global advancements in robotics technology. This year's conference is projected to assemble over 7,000 leading experts, scholars, and industry professionals to showcase cutting-edge academic achievements and emerging technological trends.

RoboSense cordially invites you to visit our booth (B064, Hall C3) at IROS 2025 to explore frontier technological developments and industrial application pathways. We look forward to collaborating with you to advance the evolution of embodied intelligent robotics.

Huatai Securities published a report expressing persistent optimism about the commercialization potential of TENCENT (00700.HK)(TCEHY.US)'s advertising over the next three years. In the context of global social advertising, domestic commercialization avenues are more diverse, and social communication traffic entry points are more concentrated.

Compared to peers like Meta (META.US) and Douyin, WeChat's advertising monetization scenarios are way beyond those of social media, extending its ecosystem to live e-commerce, mini-programs, and payments, with a stable domestic traffic foundation that is superior to the relatively fragmented public-private segmentation overseas.

TENCENT's search advertising has broad prospects, with stronger AI search content barriers (public accounts and video accounts), while the integration of Hunyuan large AI models and SaaS layout provides synergy. Meta has remarkably improved advertising efficiency through AI, and TENCENT is assumed to follow its path for improvement.

Empowered by AI, the online advertising product matrix is rapidly iterating, and advertisers' budgets are expected to lean more towards online platforms (video > text). The broker anticipated TENCENT's market share to continue rising. The ad loading rate of video accounts is still majorly lower than Douyin and Kuaishou, with long-term revenue expected to reach RMB120 billion.
~



AASTOCKS Financial News
Website: www.aastocks.com